During the corresponding time, Zai Lab Limited saw a revenue deteriorated by -6.46 % year on year, sequentially revenue fell by -21.93 %. While revenue at the Zai Lab Limited's corporate clients
Zai Lab Limited's Comment on Sales, Marketing and Customers
The company provides oncology and immunology products primarily to patients in mainland China, Hong Kong, and Macau. ZEJULA (Niraparib) is indicated for women with ovarian cancer, particularly those at high risk of recurrence following prior chemotherapy. It is used as maintenance therapy for recurrent platinum-sensitive ovarian cancer and advanced ovarian cancer responsive to platinum-based chemotherapy. ZEJULA was launched in mainland China in 2020, included in the National Reimbursement Drug List (NRDL) since 2021, and also launched in Hong Kong and Macau for similar indications. VYVGART / VYVGART Hytrulo (Efgartigimod) targets patients with generalized myasthenia gravis (gMG) in mainland China. Approximately 200,000 patients in China have myasthenia gravis, with 85% progressing to gMG and 85% of those confirmed to have AChR antibodies. The intravenous formulation of VYVGART was launched in mainland China in September 2023 and included in the NRDL since January 2024 as an add-on treatment for adult patients with AChR antibody-positive gMG. The company’s filings reference customers and markets including argenx, GSK, and Tesaro.
Zai Lab Limited, a burgeoning pharmaceutical company with listings on NASDAQ (ZLAB) and the Hong Kong Stock Exchange (9688), is set to enhance its visibility and investor engagement through participation in key investor conferences in March 2025. With events like the Leerink Partners 2025 Global Healthcare Conference and the Jefferies Biotech on the Beach Summit taking place in Miami, Florida, the company s senior management team will seize opportunities to share insights into Zai Lab s strategic direction and pipeline advancements.The Leerink Partners Global Healthcare Conference will feature a fireside chat on March 10, 2025, at 9:20 AM EST, providing a platform for Zai Lab to communicate its achievements ...
Zai Lab Limited, a global biopharmaceutical company, is making significant strides in the field of oncology through a series of clinical trials and regulatory achievements, particularly in small cell lung cancer (SCLC) and pancreatic cancer. The company s commitment to developing innovative therapies is underscored by its upcoming presentations and recent trial results. Phase 1 Trial of DLL3-Targeted ADC ZL-1310 Zai Lab announced that it will present updated data from its ongoing global Phase 1a/1b clinical trial (NCT06179069) for ZL-1310 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. ZL-1310 is a novel antibody-drug conjugate (ADC) targeting delta-like ligand 3 (DLL3), a protein of...
Zai Lab Limited, a prominent biopharmaceutical company, is poised to make significant contributions to the treatment landscape in oncology and infectious diseases. This article summarizes key developments from Zai Lab, including the presentation of preliminary data from the Phase 1 trial of ZL-1218, an investigational anti-CCR8 antibody for advanced solid tumors, insights from a study leveraging PARP inhibitors for HRD-positive ovarian cancers, and the recent NMPA approval of XACDURO for severe bacterial pneumonia. The field of pharmaceuticals is rapidly evolving, driven by innovative therapies that address critical unmet medical needs. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has emerged as a leader in t...
Zai Lab Limited, a leading biopharmaceutical company, has recently revealed the highly anticipated results from the Phase 3 NORA study, evaluating the efficacy and safety of their innovative drug, ZEJULA (niraparib), in Chinese patients diagnosed with platinum-sensitive recurrent ovarian cancer (PSROC). These findings, to be presented at prominent medical conferences in 2024, hold great promise for improving the treatment landscape for this challenging condition.The final overall survival (OS) data derived from the Phase 3 randomized, double-blind, placebo-controlled NORA study are poised to be unveiled during oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology (ESGO) i...
Shanghai and Cambridge, Mass. - Zai Lab Limited, a leading biopharmaceutical company (NASDAQ: ZLAB; HKEX: 9688), has announced that The New England Journal of Medicine (NEJM) has published data from its registrational Phase 1/2 TRIDENT-1 study, demonstrating the durable clinical activity of repotrectinib (TPX-0005) in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancers (NSCLCs). This publication provides critical i...
Zai Lab Limited’s Comment on Sales, Marketing and Customers
The company provides oncology and immunology products primarily to patients in mainland China, Hong Kong, and Macau. ZEJULA (Niraparib) is indicated for women with ovarian cancer, particularly those at high risk of recurrence following prior chemotherapy. It is used as maintenance therapy for recurrent platinum-sensitive ovarian cancer and advanced ovarian cancer responsive to platinum-based chemotherapy. ZEJULA was launched in mainland China in 2020, included in the National Reimbursement Drug List (NRDL) since 2021, and also launched in Hong Kong and Macau for similar indications. VYVGART / VYVGART Hytrulo (Efgartigimod) targets patients with generalized myasthenia gravis (gMG) in mainland China. Approximately 200,000 patients in China have myasthenia gravis, with 85% progressing to gMG and 85% of those confirmed to have AChR antibodies. The intravenous formulation of VYVGART was launched in mainland China in September 2023 and included in the NRDL since January 2024 as an add-on treatment for adult patients with AChR antibody-positive gMG. The company’s filings reference customers and markets including argenx, GSK, and Tesaro.
Sources:
Zai Lab Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Zai Lab Limited’s corporate clients.
For your research, we’ve provided 9 tables on Zai Lab Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
30.08 %